



THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Sheng C. Lou, *et al.*

Serial No.: 09/731,126

Filed: December 6, 2000

Title: MONOCLONAL ANTIBODIES TO  
HUMAN IMMUNODEFICIENCY VIRUS  
AND USES THEREOF

Attorney Docket No.: 6755.US.01

Examiner: (not yet assigned)

Group Art Unit: 1645

PATENT  
TECH CENTER 20250  
RECEIVED  
FEB 10 2003

Certificate of Mailing under 37 CFR  
§1.8(a)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Commissioner for Patents  
Washington, D.C. 20231, on:

*Kimberly A. Lorio* 2-3-03

Kimberly A. Lorio

Date

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. Applicants respectfully petition and request that the Examiner consider the listed documents and evidence such consideration by making appropriate notations on the attached form. Copies of the listed documents are attached.

Documents listed in this Supplemental Information Disclosure Statement, were first cited in a communication from a Foreign Patent Office by the European Patent Office in a counterpart international PCT application No. PCT/US01/43179. This Supplemental Information Disclosure Statement is being filed within three months of the mailing date of that communication.

Reference DE19727943 is not in the English language; therefore, Applicants submit herein the English version of the abstract of corresponding International Patent WO 98/40744. If the Examiner further requires a full translation, please contact the undersigned.

This submission does not represent that a search has been made or that no better art exists, and does not constitute an admission that each or all of the listed documents are material or constitute "prior art". If it should be determined that any of the listed documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Applicants believe no charge is required for the submission of this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 (b). However, if a fee is determined to be due, the Commissioner is hereby authorized to charge any additional filing fees required under 37 C.F.R. § 1.17 concerning this transmission, or to credit any overpayment to Deposit Account No. 01-0025. A duplicate copy of this sheet is enclosed.



23492

ABBOTT LABORATORIES  
Telephone: (847) 935-1729  
Facsimile: (847) 938-2623

Respectfully submitted,  
Sheng C. Lou, et al.

  
Cheryl L. Becker  
Cheryl L. Becker  
Registration No. 35,441  
Attorney for Applicants

DATE: February 3, 2003 SHEET 1 of 1

## Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. <b>6755.US.01</b>	SERIAL NO. <b>09/731,126</b>
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)  (37 CFR 1.98 (b))		APPLICANT(S) <b>Sheng C. Lou, et al.</b>	FILING DATE <b>December 6, 2000</b>
		GROUP <b>1645</b>	

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE
A1	5612453 A	03/18/1997	Wolf Hans, et al.			

## FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

	DOCUMENT NUMBER	PUBLIC-ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS-LATION YES NO
B1	9014358 A	11/29/1990	PCT			
B2	034561 A	12/13/1989	EPO			
B3	19727943	09/24/1998	DE			
B4	9840744	09/17/1998	PCT Abstract			

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

C1	Niedrig, M. et al., "Characterization of Murine Monoclonal Antibodies Directed Against the core Proteins of Human Immunodeficiency Virus Types 1 and 2," Journal of Virology, 65/8:4529-4533 (1991)
C2	Minassian, A.A. et al., "Monoclonal Antibodies Against Human Immunodeficiency Virus HIV Type 2 Core Proteins Cross-Reactivity With HIV Type 1 and Simian Immunodeficiency Virus," Proceedings of the national Academy of Sciences of the United States, 6/18:6939-6943 (1988)
C3	Zolla-Pazner, Susan, et al., "The Implication of Antigenic Diversity for Vaccine Development," Immunology Letters, 66/1-3: 159-164 (1999-03)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.